drugset / Trial / NCT02349607

Assessment of the Analgesic Effects of PF-05089771 and Pregabalin in Healthy Volunteers Using Evoked Pain Endpoints

NCT02349607

Phase 1 Completed 25 enrolled Pfizer
RandomizedCrossoverDouble-blindBasic science

Summary

This study will examine the activity of PF-05089771 and pregabalin, alone and in combination on a panel of evoked pain tests carried out from 0.5 to 10 hours following oral dosing in healthy male subjects

Timeline

Start
2015-01
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ibuprofen Small molecule 600 mg
Subject PF-05089771 Small molecule 300 mg Oral
Subject Pregabalin Small molecule 300 mg Oral

Indications

No indication recorded.